Search Results
Nov 06, 2025, 07:00 ET Mark Cuban Cost Plus Drug Company Expands Access with Addition of Starjemza® (ustekinumab-hmny) to Give Patients More Power Over Prescription Costs
Starjemza® will be listed at a starting price of $345 per quarter (plus shipping) for the 90 mg/mL pre-filled syringe (PFS). Additional configurations, including the 45 mg/mL and 130 mg/mL PFS, will also be offered and priced in accordance with the company's transparent cost-plus model.
More news about: Mark Cuban Cost Plus Drug Company
Nov 06, 2025, 06:59 ET Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
years of age and older) with chronic kidney disease. The product was made available in single dose vials in the following strengths: 50 mg/2.5mL, 100mg/5mL and 200mg/10mL. Capital Allocation Year-to-date,
More news about: Viatris Inc.
Nov 06, 2025, 06:45 ET Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
trial randomized 263 participants across the U.S. in a 2:1:1:1:2:1:2 ratio to receive either placebo, 1 mg, 3 mg, 6 mg or 9 mg eloralintide, or an eloralintide dose escalation of 6/9 mg or 3/6/9 mg, respectively. The primary objective of the study was to demonstrate that eloralintide is superior to placebo
More news about: Eli Lilly and Company
Nov 05, 2025, 23:08 ET HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health
endometriosis (via laparoscopy or laparotomy) were enrolled and randomly assigned in a 1:1:1:1 ratio to receive subcutaneous injections of HMI-115 (60 mg, 120 mg, or 240 mg) or placebo every two weeks for 12 weeks. The primary efficacy endpoint was the change from baseline in dysmenorrhea numeric rating scale (NRS)
More news about: Hope Medicine
Nov 05, 2025, 19:42 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
recessive disorder caused by biallelic mutations in the Lipoprotein Lipase (LPL) gene or other key regulatory genes, with fasting TG ≥10 mmol/L (885 mg/dL) and a global prevalence of 1 in 100,000–1,000,000. MCS results from a complex interaction of genetic, lifestyle, or metabolic disorders with
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 19:00 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
recessive disorder caused by biallelic mutations in the Lipoprotein Lipase (LPL) gene or other key regulatory genes, with fasting TG ≥10 mmol/L (885 mg/dL) and a global prevalence of 1 in 100,000–1,000,000. MCS results from a complex interaction of genetic, lifestyle, or metabolic disorders with
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 16:07 ET Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
was observed at 6 and 9 mg/kg doses. In addition, analysis of tumors at day 45 showed absence of viable tumor cells and presence of tumor cells in necrosis, in mice treated with PB-vcMMAE-5 at 9 mg/kg.
More news about: Precision Biologics
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
with FGFR3-altered low-grade IR NMIBC. Participants will be randomized initially to treatment with dabogratinib at 50 mg once-daily (QD) (Cohort 1) or treatment with dabogratinib at 60 mg QD (Cohort 2). The primary endpoint is complete response (CR) rate at three months. Secondary endpoints include time
More news about: Tyra Biosciences
Nov 05, 2025, 11:36 ET Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
flares that cause intense pain. Approximately 200,000 people in the United States suffer from uncontrolled gout, with serum uric acid (sUA) levels above 6 mg/dL despite treatment with oral urate lowering therapies. This leads to debilitating flares and tophi. Elevated sUA levels have also been associated with
More news about: Swedish Orphan Biovitrum AB
Nov 05, 2025, 11:08 ET The Heart of the Harvest: Meet the Farmers Bringing Potatoes to Your Table
Is an excellent source of Vitamin C, delivering 30% of the daily value. Has 620 mg of potassium, which is more than a medium-sized banana (422 mg). Has 26g of carbohydrates; carbs are the primary fuel for the brain and a key energy source
More news about: Potatoes USA
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple categories of weight loss1 Another analysis detailed an indirect trial comparison between oral semaglutide 25 mg and the currently available
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple categories of weight loss1 Another analysis detailed an indirect trial comparison between oral semaglutide 25 mg and the currently available
More news about: NOVO NORDISK INC.
Nov 05, 2025, 07:00 ET Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
enrolling MESI subjects at the 5 mg and 10 mg dose levels versus sham. About PEAK and PINNACLE The PEAK and PINNACLE studies are superiority studies evaluating two dose levels of KSI-101 (5 mg and 10 mg) compared to sham treatment in
More news about: Kodiak Sciences Inc.
Nov 05, 2025, 06:15 ET Trulieve Reports Third Quarter 2025 Results Demonstrating Operational Discipline and Cash Flow Strength
Upward THC energy drinks, and introduced five new 10mg flavors. Opened one dispensary in Cincinnati, Ohio and relocated one dispensary to Bisbee, Arizona.
More news about: Trulieve Cannabis Corp.
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
GI Tolerability: In the MAD study, MAD 1 (20 mg cohort) showed no vomiting, while MAD 2 (40 mg cohort) had events. Titrating from 2 mg to 5 mg did not cause vomiting in MAD 1, but titrating from 2 mg to 10 mg did result in vomiting in MAD 2. Compared with MAD 2, MAD 3 showed no
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 19:00 ET Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
engineering enables longer half-life than Povetacicept (TACI vTD-Fc, the clinical dosing interval is once every 4 weeks.). It is well tolerated at 200 mg/kg in monkeys. Furthermore, high concentration formulation has been developed to facilitate subcutaneous administration. IBI3034
More news about: Innovent Biologics
Nov 04, 2025, 16:11 ET Match Group Announces Third Quarter Results
YuzuTM, Salams®, HERTM, and other smaller brands. Match Group Asia ("MG Asia") consists of the world-wide activity of the brands Pairs® and Azar®.
More news about: Match Group
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
we have extended the Phase 1 study to a 48 mg dose for a total of 8 weeks to evaluate longer-term early efficacy and patient exposure to DA-1726, while also exploring the non-titrated maximum tolerated dose. We expect to read out the results from the 48 mg cohort later this year."
More news about: MetaVia Inc.
Nov 04, 2025, 16:01 ET Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
announced the first patient was enrolled in the dose expansion phase of the study, where up to 40 patients will be randomized to either 500 mg once daily or 500 mg twice daily to determine the recommended Phase 2 dose for future clinical trials. Rigel
More news about: Rigel Pharmaceuticals, Inc.
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
rocatinlimab. ROCKET ASTRO a 52-week study of rocatinlimab is complete. This study evaluated two doses of rocatinlimab (150 mg and 300 mg) as monotherapy and in combination with background low-to-medium potency topical corticosteroids and/or topical calcineurin inhibitor therapy in
More news about: Amgen
Nov 04, 2025, 09:00 ET AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
treatment and for one month after the last dose of FOTIVDA. Allergic Reaction to Tartrazine: FOTIVDA 0.89 mg capsule contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible patients.
More news about: AVEO, an LG Chem company
Nov 04, 2025, 08:30 ET Spinogenix Presents Topline Phase 2a Clinical Trial Results for SPG302, a First-in-Class ALS Treatment
SPG302 was well tolerated with no treatment-related serious adverse events over 6 months of oral daily dosing of 300mg Quantitative and objective biomarker evidence supported dose selection and a drug effect on brain areas impacted by ALS
More news about: Spinogenix
Nov 04, 2025, 08:15 ET Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
demonstrated: >95% B-cell clearance in humanized PBMC mouse models at doses as low as 0.01 mg/kg; >80% CAR expression across tissue-resident T cells with <1% off-target delivery to myeloid and hepatic
More news about: Grit Biotherapeutics Co., Ltd.
Nov 04, 2025, 08:00 ET Calliditas Therapeutics to Present at the American Society of Nephrology Kidney Week
/Kinpeygo® TARPEYO is an oral 4mg delayed-release formulation of budesonide, designed to dissolve in the pH of the distal ileum. Each capsule contains coated beads of budesonide that
More news about: Asahi Kasei Corporation
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Recent Industry Developments In August 2024, Takeda Pharmaceuticals launched NINLARO 0.5 mg capsules (ixazomib citrate) in Japan, expanding dosage flexibility for maintenance therapy in multiple myeloma. In August 2023, Janssen Biotech
More news about: DataM Intelligence 4 Market Research LLP